Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity. We wanted to evaluate the feasibility of dynamic CEUS (D-CEUS) as a predictor of early tumor response to sorafenib and to correlate functional parameters with clinical efficacy end points.
Zocco, M. A., Garcovich, M., Lupascu, A., Di Stasio, E., Roccarina, D., Annicchiarico, B. E., Riccardi, L., Ainora, M. E., Ponziani, F. R., Caracciolo, G., Rapaccini, G. L., Landolfi, R., Siciliano, M., Pompili, M., Gasbarrini, A., Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound, <<JOURNAL OF HEPATOLOGY>>, 2013; 59 (5): 1014-1021. [doi:10.1016/j.jhep.2013.06.011] [http://hdl.handle.net/10807/52141]
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound
Zocco, Maria Assunta;Garcovich, Matteo;Lupascu, Andrea;Di Stasio, Enrico;Roccarina, Davide;Annicchiarico, Brigida Eleonora;Riccardi, Laura;Ainora, Maria Elena;Ponziani, Francesca Romana;Caracciolo, Gianluigi;Rapaccini, Gian Ludovico;Landolfi, Raffaele;Siciliano, Massimo;Pompili, Maurizio;Gasbarrini, Antonio
2013
Abstract
Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity. We wanted to evaluate the feasibility of dynamic CEUS (D-CEUS) as a predictor of early tumor response to sorafenib and to correlate functional parameters with clinical efficacy end points.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
